Cited by 401Computational Drug Discovery MethodsChemical Synthesis and AnalysisEnzyme Structure and Function

The DOI matches its Crossref record; 78 of the 78 references it cites were found in a registry or an index.

Tethering: Fragment-Based Drug Discovery

Erlanson, Daniel A., Wells, James A., Braisted, Andrew C.·2004·Annual Review of Biophysics and Biomolecular Structure

DOI 10.1146/annurev.biophys.33.110502.140409

Open this paper in CoChat — free account

Abstract

▪ Abstract The genomics revolution has provided a deluge of new targets for drug discovery. To facilitate the drug discovery process, many researchers are turning to fragment-based approaches to find lead molecules more efficiently. One such method, Tethering 1 , allows for the identification of small-molecule fragments that bind to specific regions of a protein target. These fragments can then be elaborated, combined with other molecules, or combined with one another to provide high-affinity drug leads. In this review we describe the background and theory behind Tethering and discuss its use in identifying novel inhibitors for protein targets including interleukin-2 (IL-2), thymidylate synthase (TS), protein tyrosine phosphatase 1B (PTP-1B), and caspases.

Integrity signals

Registry

Crossref · 10.1146/annurev.biophys.33.110502.140409

Cites

78 of 78 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A Combinatorial Approach Defines Specificities of Members of the Caspase Family and Granzyme B
Thornberry, N. A., Rano, T. A., Peterson, E. P., Rasper, D., Timkey, T., Garcia-Calvo, M. M., Houtzager, V. M., Nordstrom, P. A., Roy, S., Vaillancourt, J. P., et al. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.29.17907 · Cited by 2,089
Discovering High-Affinity Ligands for Proteins: SAR by NMR
Shuker, S. B., Hajduk, P. J., Meadows, R. P., & Fesik, S. W. (1996) · Science · doi:10.1126/science.274.5292.1531 · Cited by 2,045
Structural Mechanism for STI-571 Inhibition of Abelson Tyrosine Kinase
Schindler, T. H., Bornmann, W. G., Pellicena, P., Miller, W. T., Clarkson, B., & Kuriyan, J. (2000) · Science · doi:10.1126/science.289.5486.1938 · Cited by 1,785
The Conformational Plasticity of Protein Kinases
Huse, M., & Kuriyan, J. (2002) · Cell · doi:10.1016/s0092-8674(02)00741-9 · Cited by 1,760
Irreversible Inhibitors of Serine, Cysteine, and Threonine Proteases
Powers, J. C., Asgian, J. L., Ekici, Ö. D., & James, K. E. (2002) · Chemical Reviews · doi:10.1021/cr010182v · Cited by 1,090 · cited 1×
“These include proteases (27, 29, 30, 57, 59, 63), kinases (24, 74), and phosphatases (4, 28, 50), all classes of enzymes that are heavily pursued in the pharmaceutical industry.”
Background
A Common Mechanism Underlying Promiscuous Inhibitors from Virtual and High-Throughput Screening
McGovern, S. L., Caselli, E., Grigorieff, N., & Shoichet, B. K. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm010533y · Cited by 1,048
Inhibition of Human Caspases by Peptide-based and Macromolecular Inhibitors
Garcia-Calvo, M. M., Peterson, E. P., Leiting, B., Ruel, R., Nicholson, D. W., & Thornberry, N. A. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.49.32608 · Cited by 980
On the attribution and additivity of binding energies
Jencks, W. P. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.7.4046 · Cited by 938
Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site
Pargellis, C., Tong, L., Churchill, L., Cirillo, P. F., Gilmore, T., Graham, A. G., Grob, P. M., Hickey, E. R., Moss, N., Pav, S., et al. (2002) · Nature Structural Biology · doi:10.1038/nsb770 · Cited by 834
Unraveling hot spots in binding interfaces: progress and challenges
DeLano, W. L. (2002) · Current Opinion in Structural Biology · doi:10.1016/s0959-440x(02)00283-x · Cited by 767

Show all 78 references

Research works printed but not linked: 1

Graczyk PP, 1999, Restor. Neurol. Neurosci., 14, 1

Sorted by citations

Items 301–400 of 401

Fragment‐Based Lead Discovery
Albert, J. S. (2010) · Wiley eBooks · doi:10.1002/9780470584170.ch4 · Cited by 7
Application of covalent modality in proximity-induced drug pharmacology: Early development, current strategy, and feature directions
Li, L., Liu, S., & Luo, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116394 · Cited by 6
Fluoromethylketone‐Fragment Conjugates Designed as Covalent Modifiers of Ec DsbA are Atypical Substrates
Doak, B. C., Whitehouse, R. L., Rimmer, K. A., Williams, M. L., Heras, B., Caria, S., Ilyichova, O. V., Vazirani, M., Mohanty, B., Harper, J. B., et al. (2024) · ChemMedChem · doi:10.1002/cmdc.202300684 · Cited by 6
Fragments to link. A multiple docking strategy for second site binders
Vass, M., & Keserű, G. M. (2012) · MedChemComm · doi:10.1039/c2md20267k · Cited by 6
Transition State Analogues Enhanced by Fragment-Based Structural Analysis: Bacterial Methylthioadenosine Nucleosidases
Zhang, D., Burdette, B. E., Wang, Z., Karn, K., Li, H., Schramm, V. L., Tyler, P. C., Evans, G. B., & Wang, S. (2020) · Biochemistry · doi:10.1021/acs.biochem.9b01092 · Cited by 6
Antibody surrogates click into place
Kodadek, T. J. (2009) · Nature Chemistry · doi:10.1038/nchem.228 · Cited by 6
The use of combinatorial chemistry methodologies to discover novel chemotherapeutic agents
Edwards, P. J. (2008) · Drug Discovery Today · doi:10.1016/j.drudis.2008.11.008 · Cited by 6
Molecular basis of cytokine signalling – theme and variations
Sebald, W., Nickel, J., Zhang, J.-L., & Mueller, T. D. (2009) · FEBS Journal · doi:10.1111/j.1742-4658.2009.07480.x · Cited by 8
New Applications for Structure-Based Drug Design
Murray, C. W., & Hartshorn, M. J. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00277-7 · Cited by 6
Fragment‐Based Ligand Discovery
Davis, B. J., & Hubbard, R. E. (2020) · Wiley eBooks · doi:10.1002/9781118681121.ch4 · Cited by 6
Druggability Prediction
Álvarez-García, D., Seco, J., Schmidtke, P., & Barril, X. (2012) · Wiley eBooks · doi:10.1002/9783527645947.ch13 · Cited by 6
Reduced dimensionality (4,3)D-hnCOCANH experiment: an efficient backbone assignment tool for NMR studies of proteins
Kumar, D. (2013) · Journal of Structural and Functional Genomics · doi:10.1007/s10969-013-9161-y · Cited by 5
Small Molecule Ion Channel Match Making: A Natural Fit for New ASIC Ligands
Bagriantsev, S. N., & Minor, D. L. (2010) · Neuron · doi:10.1016/j.neuron.2010.09.038 · Cited by 5
Structure-based Design Technology C ONTOUR and its Application to Drug Discovery
Liu, Z., Lindblom, P., Claremon, D. A., & Singh, S. B. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849735056-00265 · Cited by 5
- Library Design, Chemical Space, and Drug Likeness
Villar, H. O. (2015) · CRC Press eBooks · doi:10.1201/b18799-8 · Cited by 5
Targeting Protein–Protein Interactions of Tyrosine Phosphatases with Microarrayed Fragment Libraries Displayed on Phosphopeptide Substrate Scaffolds
Hogan, M., Bahta, M., Tsuji, K., Nguyen, T. X., Cherry, S., Lountos, G. T., Tropea, J. E., Zhao, B. M., Zhao, X. Z., Waugh, D. S., et al. (2019) · ACS Combinatorial Science · doi:10.1021/acscombsci.8b00122 · Cited by 5
Molecular Docking-assisted Protein Chip Screening of Inhibitors for Bcl-2 Family Protein-protein Interaction to Discover Anticancer Agents by Fragment-based Approach
Yoou, M., Cho, S., & Choi, Y. (2019) · BioChip Journal · doi:10.1007/s13206-019-3306-4 · Cited by 5
Identifying Ortholog Selective Fragment Molecules for Bacterial Glutaredoxins by NMR and Affinity Enhancement by Modification with an Acrylamide Warhead
Khattri, R. B., Morris, D. L., Bilinovich, S. M., Manandhar, E., Napper, K. R., Sweet, J. W., Modarelli, D. A., & Leeper, T. C. (2019) · Molecules · doi:10.3390/molecules25010147 · Cited by 5
Making FBDD Work in Academia
Bulfer, S. L., Jean-Francois, F. L., & Arkin, M. R. (2016) · Methods and principles in medicinal chemistry · doi:10.1002/9783527683604.ch10 · Cited by 5
A Global Ligandability Map of Tryptoline Butynamide Stereoprobes Identifies Covalent Inhibitors of the Actin Maturation Protease
Xiong, Y., Reinhardt, C. J., Nguyen, T., Hoffman, M. A., Simon, G. M., Melillo, B. N., & Cravatt, B. F. (2026) · Journal of the American Chemical Society · doi:10.1021/jacs.6c03985 · Cited by 5
Discovery of Covalent Lead Compounds Targeting 3CL Protease with a Lateral Interactions Spiking Neural Network
Gu, Z., Yan, Y. J., Liu, H., Wu, D., Yao, H., Lin, K., & Li, X. (2024) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.3c01900 · Cited by 4
Targeting a Cryptic Pocket in a Protein–Protein Contact by Disulfide-Induced Rupture of a Homodimeric Interface
Nguyen, D., Xie, X., Jakobi, S., Terwesten, F., Metz, A., Nguyen, T. X. P., Palchykov, V. A., Heine, A., Reuter, K., & Klebe, G. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00296 · Cited by 4
Covalent fragment screening
Shraga, A., Resnick, E., Gabizon, R., & London, N. (2021) · Annual reports in medicinal chemistry · doi:10.1016/bs.armc.2021.04.001 · Cited by 5
Fragment-Based Lead Discovery Applied to Protein–Protein Interactions
Hubbard, R. E. (2015) · Royal Society of Chemistry eBooks · doi:10.1039/9781782620938-00126 · Cited by 4
Fragment-based De Novo Design of Drug-like Molecules
Proschak, E., Tanrikulu, Y., & Schneider, G. (2008) · Royal Society of Chemistry eBooks · doi:10.1039/9781847558879-00217 · Cited by 4
Fragment‐Based Drug Discovery of Kinase Inhibitors
Erlanson, D. A. (2009) · Wiley eBooks · doi:10.1002/9780470524961.ch18 · Cited by 4
Self-citation
Discovering New Drug-Targeting Sites on Flexible Multidomain Protein Kinases
Harris, T. K. (2006) · Humana Press eBooks · doi:10.1385/1-59259-964-8:199 · Cited by 4
Fragment‐Based Lead Generation
Efremov, I. V., & Erlanson, D. A. (2016) · Methods and principles in medicinal chemistry · doi:10.1002/9783527677047.ch06 · Cited by 4
Self-citation
A Glutathione S-Transferase Pi Molecular Glue Tethers Splicing Factors and Remodels Cell Metabolism
Leace, D. M., Ware, M. L., Murtagh, O. L., Tsai, H.-K., Chang, C., & Hsu, K. (2025) · Journal of the American Chemical Society · doi:10.1021/jacs.5c06951 · Cited by 3
Computational approach to site‐directed ligand discovery
Tóth, G., Mukhyala, K., & Wells, J. A. (2007) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.21402 · Cited by 3
Self-citation
Development of disulfide-functionalized peptides covalently binding G protein-coupled receptors
Einsiedel, J., Schmidt, M. F., Hübner, H., & Gmeiner, P. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116720 · Cited by 3
Computational Fragment-Based Drug Design
Sheng, C., Dong, G., & Wang, C. (2015) · Methods in pharmacology and toxicology · doi:10.1007/7653_2015_51 · Cited by 3
Chemical Translational Biology: Redefining Druggability of Protein‐Protein Interactions
Cesa, L. C. (2020) · ChemBioChem · doi:10.1002/cbic.202000532 · Cited by 3
Fragment hopping protocol for the design of small-molecule protein–protein interaction inhibitors
Kell, S. R., Wang, Z., & Ji, H. (2022) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2022.116879 · Cited by 3
Fragment-based Drug Discovery: the Shape of Things to Come
Drysdale, M. J. (2013) · Australian Journal of Chemistry · doi:10.1071/ch13255 · Cited by 3
Tethering: Fragment‐Based Drug Discovery by Mass Spectrometry
Cancilla, M. T., & Erlanson, D. A. (2007) · Methods and principles in medicinal chemistry · doi:10.1002/9783527610907.ch9 · Cited by 3
Self-citation
Conception d'un logiciel de docking et applications dans la recherche de nouvelles molécules actives
Grosdidier, A. (2007) · HAL · Cited by 3
Site‐Directed Fragment Discovery for Allostery
Rettenmaier, T. J., Hudson, S. A., & Wells, J. A. (2016) · Methods and principles in medicinal chemistry · doi:10.1002/9783527683604.ch11 · Cited by 3
Self-citation
Covalent Modifier Discovery Using Hydrogen/Deuterium Exchange–Mass Spectrometry
Kojima, H., Yanagi, R., Higuchi, E., Yoshizawa, M., Shimodaira, T., Kumagai, M., Kyoya, T., Sekine, M., Egawa, D., Ohashi, N., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c01986 · Cited by 2
Drug leads for interactive protein targets with unknown structure
Fernández, A., & Scott, R. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.10.006 · Cited by 2
Library Design, Chemical Space, and Drug Likeness
Villar, H. O. (2015) · CRC Press eBooks · doi:10.1201/b18799-5 · Cited by 2
Identification of Cysteine 270 as a Novel Site for Allosteric Modulators of SARS‐CoV‐2 Papain‐Like Protease**
Hu, H., Wang, Q., Su, H., Shao, Q., Zhao, W., Chen, G., Li, M., & Xu, Y. (2022) · Angewandte Chemie · doi:10.1002/ange.202212378 · Cited by 2
Drug Design Methods to Regulate Protein–Protein Interactions
Poluri, K. M., Gulati, K., Tripathi, D. K., & Nagar, N. (2023) · Springer eBooks · doi:10.1007/978-981-99-2423-3_6 · Cited by 2
NMR Spectroscopy in Fragment Based Drug Design
Pellecchia, M. (2009) · Topics in medicinal chemistry · doi:10.1007/7355_2009_5 · Cited by 2
Fragment‐Based Approaches in Virtual Screening
Danzhi Huang, A., & Caflisch, A. (2011) · Methods and principles in medicinal chemistry · doi:10.1002/9783527633326.ch17 · Cited by 2
Protein X ‐Ray Crystallography in Drug Discovery
Nollert, P., Feese, M. D., Staker, B. L., & Kim, H. (2010) · Wiley eBooks · doi:10.1002/9780470571224.pse011 · Cited by 2
Disulfide tethering reveals cryptic pockets in oncogenic KRAS
Balius, T. E., Dyba, M. D., Kumari, V., Denson, J. L., Yi, M., Sharma, A. K., Prakash, P., Alberico, E. O., Messing, S. A. J., Wall, V. E., et al. (2026) · Communications Chemistry · doi:10.1038/s42004-026-01992-x · Cited by 1
Chapter 11 Recent Advances in Design of Small-Molecule Ligands to Target Protein–Protein Interactions
Yang, C.-Y., & Wang, S. (2006) · Annual reports in computational chemistry · doi:10.1016/s1574-1400(06)02011-1 · Cited by 1
A century at the chemistry-biology interface
Kohler, J. J. (2006) · Nature Chemical Biology · doi:10.1038/nchembio0606-288 · Cited by 1
Screening and biophysics in small molecule discovery
Wilson, C. G. M., & Arkin, M. R. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818349-6.00005-4 · Cited by 1
Treatment of Cancer Using Combination of Herbal and Novel Drug Delivery System
Kale, N. (2023) · Springer eBooks · doi:10.1007/978-3-031-28780-0_49 · Cited by 1
Drug discovery processes: When and where the rubber meets the road
Miller, S. M., Moos, W. H., Munk, B. H., Munk, S. A., Hart, C. P., & Spellmeyer, D. C. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-824304-6.00025-0 · Cited by 1
Fragment‐Based Drug Design: Considerations for Good ADME Properties
Ji, H. (2010) · Wiley eBooks · doi:10.1002/9780470915110.ch11 · Cited by 1
Case Study 3: Fragment Hopping to Design Highly Potent and Selective Neuronal Nitric Oxide Synthase Inhibitors
Ji, H., & Silverman, R. B. (2013) · Methods and principles in medicinal chemistry · doi:10.1002/9783527665143.ch18 · Cited by 1
Rational Inhibitors of DNA Base Excision (BER) Enzymes: New Tools for Elucidating the Role of BER in Cancer Chemotherapy
Krosky, D. J., & Stivers, J. T. (2004) · Defense Technical Information Center (DTIC) · doi:10.21236/ada424155
New Paradigm for Integrase Inhibition: Blocking Enzyme Function without Directly Targeting the Active Site
Al‐Mawsawi, L. Q., & Neamati, N. (2011) · Wiley eBooks · doi:10.1002/9781118015377.ch29
Discovery of Inhibitors of Protein–Protein Interactions by Screening Chemical Libraries
Garcı́a-Echeverrı́a, C. (2010) · Wiley eBooks · doi:10.1002/9780470972137.ch6
Dynamic Covalent Capture: A Sensitive Tool for Detecting Molecular Interactions
Prins, L. J. (2010) · Wiley eBooks · doi:10.1002/9783527630554.ch7
TETHERING: A NOVEL TOOL IN DRUG DISCOVERY
Rupali, Y., Jagdale, D. M., & Vilasrao, K. (2014) · Indo American Journal of Pharmaceutical Research
Evaluation of Molecular Inhibitors of the c-Myc Oncoprotein
Prochownik, E. V. (2005) · Defense Technical Information Center (DTIC) · doi:10.21236/ada434552
Drug Discovery in the Post-Genomic Era: Systems-Based Drug Discovery
Hu, Z. (2007) · International Conference on Bioinformatics and Biomedical Engineering · doi:10.1109/icbbe.2007.107
Rational design of small-molecule inhibitors of protein-protein interactions: Application to the oncogenic c-Myc/Max interaction
Meireles, L. (2011) · D-Scholarship@Pitt (University of Pittsburgh)
THE N-END RULE PATHWAY: MOLECULAR PRINCIPLES OF STRUCTURAL RECOGNITION AND RATIONAL DESIGN OPPORTUNITIES
Sriram, S. (2012) · D-Scholarship@Pitt (University of Pittsburgh)
GPCR 3D modeling
Axe, F. U. (2010) · Cambridge University Press eBooks · doi:10.1017/cbo9780511730412.018
Expanding the Target Space: Druggability Assessments
Schmidtke, P., Álvarez-García, D., Seco, J., & Barril, X. (2012) · Royal Society of Chemistry eBooks · doi:10.1039/9781849735377-00302
Structure-Based Drug Discovery Without Structure: Working Around the Paradox to Disrupt Protein-Protein Associations
Fernández, A. (2016) · Soft and biological matter · doi:10.1007/978-3-319-30852-4_16
Drug-Based Disruption of Protein Complexes with Unknown Structure: Towards a Novel Platform for Drug Discovery
Fernández, A. (2015) · Journal of Pharmacogenomics & Pharmacoproteomics · doi:10.4172/2153-0645.1000e149
IDENTIFYING SELECTIVE LIGANDS FOR GLUTAREDOXIN PROTEINS WITH FRAGMENT BASED DRUG DESIGN APPROACH AND OPTIMIZATION OF THE BACTERIAL SELECTIVE HITS
Khattri, R. B. (2016) · OhioLink ETD Center (Ohio Library and Information Network) · doi:10.13140/rg.2.2.34723.58400
Activation and Inhibition of Biological Function through Design of Novel Protein-Ligand Interactions
Budiardjo, S. J. (2019) · KU ScholarWorks (The University of Kansas)
Leitstrukturoptimierung für Antiprotozoika und Erfolgreiche Leitstruktursuche für Metalloproteinasen: Ein Fragment-basiertes Virtuelles Screening Verfahren
Silber, K. (2007) · Publikationsserver (Universitat Marburg) · doi:10.17192/z2007.0753
Adventures in Small Molecule Fragment Screening by X-ray Crystallography
Bauman, J. D., Patel, D., & Arnold, E. (2015) · NATO science for peace and security series. A, Chemistry and biology · doi:10.1007/978-94-017-9719-1_15
References
(2012) · Wiley eBooks · doi:10.1002/9783527644506.refs
Bibliography
(2009) · Wiley eBooks · doi:10.1002/9780470551455.biblio
Structure-based Search for novel c-di-AMP Synthase Inhibiting Fragments
Garbers, T. B. (2023) · eDiss (Georg-August-Universität Göttingen) · doi:10.53846/goediss-9806
Fragment-based Ligand Discovery (FBLD)
Hubbard, R. E. (2023) · Royal Society of Chemistry eBooks · doi:10.1039/9781788018982-00188
Entwicklung von chemischen Tools für nukleäre Rezeptoren
Arifi, S. (2023) · Publication Server of Goethe University Frankfurt am Main (Goethe University Frankfurt) · doi:10.21248/gups.81648
Mise en place d'une approche de criblage de fragments pour la découverte de molécules à visée thérapeutique : application à la conception d'inhibiteurs des cyclophilines humaines.
Colliandre, L. (2010) · theses.fr (ABES) · doi:10.70675/1cf44db5z8119z4472zb282zcab6dbb4211b
Reconnaissance de surfaces de protéines par des foldamères aromatiques
Stupfel, M. (2010) · theses.fr (ABES) · doi:10.70675/f40d5515z53f5z4c2fz91b2z4df5dd85df3c
Fluorescence polarization-based fragment screen identifies inhibitors of APOBEC3A and APOBEC3BPreprint
Brunello, J. S., Allegakoen, H. R., Li, W., Revalde, J. L., Bhadoria, R., Sanders, C. M., Arkin, M. R., & Ostrem, J. M. L. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.31.742089
BindingDB Entry 50045890: Progress in discovery of small-molecule modulators of protein-protein interactions via fragment screening.
BindingDB (2016) · UC San Diego · doi:10.7270/q2sf2xvc
BindingDB Entry 50020161: Advances of bioorthogonal coupling reactions in drug development.
BindingDB (2024) · UC San Diego · doi:10.7270/q2th8s34
BindingDB Entry 50031673: A rapid oxime linker-based library approach to identification of bivalent inhibitors of the Yersinia pestis protein-tyrosine phosphatase, YopH.
BindingDB (2010) · UC San Diego · doi:10.7270/q2319w2z
BindingDB Entry 1887: A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design.
BindingDB (2007) · UC San Diego · doi:10.7270/q21n7zcn
BindingDB Entry 50008819: Optimization of novel reversible Bruton's tyrosine kinase inhibitors identified using Tethering-fragment-based screens.
BindingDB (2021) · UC San Diego · doi:10.7270/q2tx3jsf
BindingDB Entry 50037270: Fragment-based drug discovery.
BindingDB (2012) · UC San Diego · doi:10.7270/q2nc61zj
BindingDB Entry 50015613: Virtual screening of human 5-aminoimidazole-4-carboxamide ribonucleotide transformylase against the NCI diversity set by use of AutoDock to identify novel nonfolate inhibitors.
BindingDB (2009) · UC San Diego · doi:10.7270/q2pz589q
BindingDB Entry 50038213: Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase.
BindingDB (2012) · UC San Diego · doi:10.7270/q23r0tqg
BindingDB Entry 50016555: X-ray Screening of an Electrophilic Fragment Library and Application toward the Development of a Novel ERK 1/2 Covalent Inhibitor.
BindingDB (2023) · UC San Diego · doi:10.7270/q23t9n77
BindingDB Entry 50032123: Deconstructing fragment-based inhibitor discovery.
BindingDB (2011) · UC San Diego · doi:10.7270/q2fn16df
BindingDB Entry 50030526: Rapid identification of improved protein ligands using peptoid microarrays.
BindingDB (2010) · UC San Diego · doi:10.7270/q25q4w5x
BindingDB Entry 3572: Impact of linker strain and flexibility in the design of a fragment-based inhibitor.
BindingDB (2011) · UC San Diego · doi:10.7270/q2w37tp8
BindingDB Entry 50004800: Structure-based redesign of an edema toxin inhibitor.
BindingDB (2020) · UC San Diego · doi:10.7270/q2pk0k15
BindingDB Entry 4989: On-chip fragment-based approach for discovery of high-affinity bivalent inhibitors.
BindingDB (2012) · UC San Diego · doi:10.7270/q2w094g1
BindingDB Entry 50034066: A novel potential therapeutic avenue for autism: design, synthesis and pharmacophore generation of SSRIs with dual action.
BindingDB (2012) · UC San Diego · doi:10.7270/q23b60jf
BindingDB Entry 50047988: Discovery of Cell-Permeable O-GlcNAc Transferase Inhibitors via Tethering in Situ Click Chemistry.
BindingDB (2018) · UC San Diego · doi:10.7270/q20g3n47
BindingDB Entry 50037318: Integrating fragment assembly and biophysical methods in the chemical advancement of small-molecule antagonists of IL-2: an approach for inhibiting protein-protein interactions.
BindingDB (2012) · UC San Diego · doi:10.7270/q2tq6280
BindingDB Entry 50002091: Application of covalent modality in proximity-induced drug pharmacology: Early development, current strategy, and feature directions.
BindingDB (2026) · UC San Diego · doi:10.7270/q2qj7p3x
BindingDB Entry 50020710: Halo Library, a Tool for Rapid Identification of Ligand Binding Sites on Proteins Using Crystallographic Fragment Screening.
BindingDB (2024) · UC San Diego · doi:10.7270/q2cj8jzr
BindingDB Entry 50017174: Development of disulfide-functionalized peptides covalently binding G protein-coupled receptors.
BindingDB (2023) · UC San Diego · doi:10.7270/q2jd51v7
BindingDB Entry 50016249: Boosting the Discovery of Small Molecule Inhibitors of Glucose-6-Phosphate Dehydrogenase for the Treatment of Cancer, Infectious Diseases, and Inflammation.
BindingDB (2023) · UC San Diego · doi:10.7270/q28g8qpm

Authors: Erlanson, D. A., Wells, J. A., & Braisted, A. C.
Affiliations: Sunesis (United States) (US)
ORCID: Erlanson, Daniel A.
Wells, James A.
Venue: Annual Review of Biophysics and Biomolecular Structure
Publisher: Annual Reviews
Published: 2004-06-09
Volume: 33
Issue: 1
Pages: 199-223
ISSN: 1056-8700 (ISSN-L)
1545-4266
DOI: 10.1146/annurev.biophys.33.110502.140409
OpenAlex: W2138958920
Cited by: 385
References: 78
Citations by year: 2026: 5 · 2025: 7 · 2024: 17 · 2023: 16 · 2022: 17 · 2021: 8 · 2020: 17 · 2019: 17 · 2018: 21 · 2017: 6 · 2016: 18 · 2015: 21 · 2014: 23 · 2013: 11 · 2012: 29
FWCI: 1.77
Type: journal article
Language: en
Open access: closed
Locations: Annual Review of Biophysics and Biomolecular Structure (publishedVersion)
PubMed (publishedVersion)
Funders: Sunesis
Topics: Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
Keywords: tethering, fragment-based drug discovery, small-molecule fragments, protein-ligand binding, lead compound identification, interleukin-2, thymidylate synthase, PTP1B, caspases, protein inhibitors
MeSH terms: Binding Sites, Peptide Fragments, Protein Binding, Proteins, Drug Design, Protein Interaction Mapping, Protein Array Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Tethering: Fragment-Based Drug Discovery

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks